OptimizeRx Expands Omni-channel Platform Reach at Point-Of-Care
27 Aprile 2021 - 1:51PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science
companies, physicians and patients, has announced its
latest platform expansion at point-of-care with several new health
information technology (HIT) partnerships to further connect the
digital channels used by healthcare professionals (HCPs) within the
care setting. The expansion increases the reach of the OptimizeRx
digital health and communications platform, unlocking new
touchpoints for life science companies to engage providers both
within and outside the electronic health record (EHR). The
increased touchpoints amplify physician mindshare, and further
diversify the platform’s channel mix to address clients’ challenges
of customer access.
The platform growth advances OptimizeRx's mission to improve
affordability, access, and adherence for patients by unlocking
omni-channel avenues for life sciences organizations to engage in
more meaningful ways with both HCPs and patients. Moreover, the
partnerships particularly strengthen its platform's ability to
address the unique challenges along the oncology care journey.
Increasing Access to Resources for
OncologistsThe recent OptimizeRx partnerships
significantly increase the platform’s touchpoints with oncologists,
providing opportunities for pharmaceutical manufacturers to engage
in new ways more than 50% of all oncologists in the U.S.
A recent McKinsey analysis cited “stakeholder engagement” as one
of the top-five success factors for treatment manufacturers in
effectively commercializing oncology treatments, given the
increasing availability of precision medicine and explosion of new
cancer treatments.
“No one needs personalized and specialized resources right now
more than oncologists,” said OptimizeRx chief commercial officer,
Steve Silvestro. “In 2020, we demonstrated our commitment to
enabling the ‘hyper-personalization’ of treatment information
available at the point-of-care with the integration of real-world
data to our platform. With these new partnerships, we’ve built the
most comprehensive platform connecting life sciences and
oncologists, and the market is responding,” concluded Mr.
Silvestro.
Omni-channel ExpansionThis latest extension of
the OptimizeRx digital health and communications platform allows
life sciences to leverage digital channels more effectively at the
point-of-care to deliver contextual resources at more points along
the care journey.
The new HIT partnerships expand the OptimizeRx platform EHR
reach within the Epic, Cerner, and Athena systems, as well as
outside the EHR on other platforms and technology-enabled devices
that HCPs use to deliver care. Beyond the EHR, physicians engage
with ever-expanding digital channels to access all the resources
they need to deliver the best care to their patients– including
desk research and peer-to-peer collaboration.
“Reaching providers everywhere they consume relevant medical
information throughout their daily journeys, has become
increasingly difficult as digital channels grow more fragmented,”
commented OptimizeRx CEO, William Febbo. “As the number of more
diverse and digitally native practitioners grows, it’s important
that life sciences stay ahead of the curve to engage them with
personalized and contextual content, within the most effective
channels. Our latest partnerships execute on our team’s
forward-thinking approach to bridging the gaps in communication
between life sciences and providers for the good of patient care,
which directly increases the total market opportunity and augments
the near-term revenue growth,” concluded Mr. Febbo.
About OptimizeRx OptimizeRx is a digital
health company that provides communications solutions for life
science companies, physicians and patients. Connecting
over half of healthcare providers in the U.S. and millions of
patients through a proprietary network, the OptimizeRx digital
health platform helps patients afford and stay on medications. The
platform unlocks new patient and physician touchpoints for life
science companies along the patient journey, from point-of-care, to
retail pharmacy, through mobile patient engagement.For more
information, follow the company on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements This press release contains
forward-looking statements within the definition of Section 27A of
the Securities Act of 1933, as amended, and such as in Section 21E
of the Securities Exchange Act of 1934, as amended. These
forward-looking statements should not be used to make an investment
decision. The words 'estimate,' 'possible' and 'seeking' and
similar expressions identify forward-looking statements, which
speak only as to the date the statement was made. The company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results
could differ materially from those set forth in, contemplated by,
or underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel (248)
651-6568 (x807)dbaker@optimizerx.com Media Relations
Contact Maira Alejandra, Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Grafico Azioni OptimizeRx (NASDAQ:OPRX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OptimizeRx (NASDAQ:OPRX)
Storico
Da Lug 2023 a Lug 2024